Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

NCT04543279 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT04543279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04543279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Terminated
Start date
May 3, 2021
Completion date
July 30, 2022
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, thrombocytopenia